Evidence map›Paper›PMID 35951427›Full record

ArticleJCI insight2022

CDCP1 regulates retinal pigmented epithelial barrier integrity for the development of experimental autoimmune uveitis.

Lingjun Zhang, Nozha Borjini, Yu Lun, Sweta Parab, Gospel Asonye, Rupesh Singh, Brent A Bell, Vera L Bonilha, Andrei Ivanov, David A Fox and 2 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Lingjun ZhangDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Nozha BorjiniDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Yu LunDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Sweta ParabDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Gospel AsonyeDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Rupesh SinghDepartment of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Brent A BellDepartment of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Vera L BonilhaDepartment of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Andrei IvanovDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
David A FoxDivision of Rheumatology and Clinical Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, Michigan, USA.
Rachel R CaspiLaboratory of Immunology, National Eye Institute, NIH, Bethesda, Maryland, USA.
Feng LinDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · USNational Eye Institute · USUniversity of Michigan · US

Funding

Genetic, Cellular and Molecular Mechanisms in Autoimmunity to RetinaZIAEY000184 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 2009 to 2025
$51.7M
RESOURCE/SERVICE CORE C - MOLECULAR INFORMATICS MODULEP30EY025585 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI BELA ANAND-APTE · 2016 to 2026
$7.7M
Role of CDCP1 in the pathogenesis of autoimmune uveitisR01EY034077 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI FENG C LIN · 2023 to 2026
$2.0M
Role of CD6 in the pathogenesis of autoimmune uveitisR01EY025373 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C · 2017 to 2021
$2.0M
A novel regulator of corneal wound healing and Pseudomonas aeruginosa keratitisR01EY030111 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C, TAM, K. P. CONNIE · 2019 to 2022
$1.6M
University of Michigan Clinical Autoimmunity Center of ExcellenceUM1AI144298 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN, KHANNA, DINESH · 2019 to 2023
$546k
Development of a novel antibody-drug conjugate for treating T-cell lymphoma.R41CA275639 · NCI · ABCON THERAPEUTICS, INC. · PI LIN, FENG C · 2022 to 2022
$403k
Development of new models of AMDR21EY031087 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C · 2019 to 2019
$348k
NCI NIH HHS R41 CA275639NEI NIH HHS P30 EY025585NEI NIH HHS R01 EY025373NEI NIH HHS R01 EY030111NEI NIH HHS R01 EY034077NEI NIH HHS R21 EY031087NIAID NIH HHS UM1 AI144298
6 · The paper itself

Abstract

Cub domain-containing protein 1 (CDCP1) is a protein that is highly expressed on the surface of many cancer cells. However, its distribution in normal tissues and its potential roles in nontumor cells are poorly understood. We found that CDCP1 is present on both human and mouse retinal pigment epithelial (RPE) cells. CDCP1-KO mice developed attenuated retinal inflammation in a passive model of autoimmune uveitis, with disrupted tight junctions and infiltrating T cells detected in RPE flat mounts from WT but not CDCP1-KO mice during EAU development. Mechanistically, we discovered that CDCP1 on RPE cells was upregulated by IFN-γ in vitro and after EAU induction in vivo. CD6 stimulation induced increased RPE barrier permeability of WT but not CDCP1-knockdown (CDCP1-KD) RPE cells, and activated T cells migrated through WT RPE monolayers more efficiently than the CDCP1-KD RPE monolayers. In addition, CD6 stimulation of WT but not the CDCP1-KD RPE cells induced massive stress fiber formation and focal adhesion disruption to reduce cell barrier tight junctions. These data suggest that CDCP1 on RPE cells interacts with CD6 on T cells to induce RPE cytoskeleton remodeling and focal adhesion disruption, which open up the tight junctions to facilitate T cell infiltration for the development of uveitis.

Indexed as

Antigens, NeoplasmCell Adhesion MoleculesRetinal PigmentsUveitisAnimalsHumansInflammationMiceRetinaTight JunctionsAntigens, NeoplasmCDCP1 protein, humanCDCP1 protein, mouseCell Adhesion MoleculesRetinal PigmentsAutoimmune diseasesAutoimmunity

Identifiers

PMID35951427
PMCPMC9675461
OpenAlexW4291020175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.